Will S&P 500 open higher? Polymarket odds sit at 52% as Wall Street weighs 5.35% Treasury yields

First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on re

First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on r

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the di

Two-year extension builds on productive relationship established in 2019 Nurix continues to retain c

BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clin

Bank of America Corp DE acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX) in

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference

Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference

Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potent

Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clin

Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and

BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clini

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high durin

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform a

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has ea

Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients w

Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key dru

UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clini

Amova Asset Management Americas Inc. cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ:

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by

Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform a

Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises th

BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Bu

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks C

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the ana

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the di

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a B

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR

BTIG analyst Jeet Mukherjee maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the

Jefferies analyst Roger Song maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the pri

Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Ph

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in